GLP-1 Therapies Newsletter
Issue #61November 2, 20267 studies

A new triple-receptor drug hit 28% weight loss in phase 3 — but full trial data aren't published yet

GLP-1 drugs are everywhere — in diabetes clinics, weight-loss offices, and now oncology wards, cardiology suites, and addiction medicine.

This week's research asks the harder questions: what happens when you stop taking them, who can't access them, and how far can the next generation go?

🔬 Retatrutide: Three receptors, 28% weight loss, and a lot of asterisks

  • Retatrutide hits three metabolic receptors at once — the same two targeted by tirzepatide, plus a glucagon receptor — and phase 3 sponsor disclosures report mean weight reductions of 28.3% at 80 weeks and 28.7% at 68 weeks in obesity trials. Those numbers are striking. They're also provisional: only one phase 3 trial (in early type 2 diabetes) has a full peer-reviewed report. The obesity results are currently topline sponsor disclosures, not published trial data.
  • The drug's molecular design is genuinely novel — a 39-amino-acid peptide engineered to balance incretin activity with glucagon receptor engagement while keeping blood sugar stable. But that glucagon component raises real questions about lean mass loss, heart rate changes, and gastrointestinal tolerability that the full data haven't yet resolved.
  • The catch: estimands matter here. A "treatment-regimen" estimate from the same trial came in at 25% — still large, but a meaningful gap from the headline 28.3% figure, depending on how discontinuations are handled.

Why it matters: Retatrutide could represent a step-change in obesity pharmacology, but interpreting it responsibly requires waiting for the peer-reviewed trial reports.

Top 20% journal 🔗 Pharmaceutics Review 🗓️ Oct 27

Key Findings

💊 Tirzepatide edges semaglutide on gallstone risk in 242,000-patient study

  • In a propensity-matched real-world comparison, semaglutide users had an 11% higher rate of gallstones and a 22% higher rate of gallbladder inflammation than tirzepatide users over one year.
  • Both drugs still looked better than DPP-4 inhibitors across biliary and pancreatic outcomes — including a 32% lower rate of acute pancreatitis — so the headline isn't that GLP-1 drugs are risky; it's that they're not all identical.
💡 Tirzepatide's gallbladder edge over semaglutide is real, but both beat older alternatives.
Top 20% journal 🔗 Journal of clinical medicine Journal Article 🗓️ Oct 27

🧠 GLP-1 drugs and cognition: the evidence is thinner than the headlines

  • A meta-analysis of five randomized controlled trials covering 13,711 participants found no statistically significant effect of GLP-1 drugs on global cognition, attention, or other cognitive domains in adults at risk for Alzheimer's disease.
  • Only four trials contributed usable data, and a sensitivity analysis removing the largest single trial left the pooled estimate imprecise and inconclusive. The researchers call current findings "exploratory and hypothesis-generating."
💡 Randomized evidence for GLP-1 drugs improving cognition doesn't exist yet.
🎖️ Top 10% journal 🔗 Nutrients Systematic Review 🗓️ Oct 27

⚖️ Stopping GLP-1 drugs means the weight comes back — and so does the cardiometabolic risk

  • A systematic review confirms what clinical intuition already suggested: weight regain and loss of cardiometabolic benefit are common after discontinuing GLP-1 or dual GLP-1/GIP drugs, and maintenance strategies remain poorly characterized.
  • The finding reframes these medications less as courses of treatment and more as chronic therapies — which has direct implications for coverage decisions and how insurers approach prior authorization.
💡 GLP-1 benefits reverse after stopping; the drug-as-chronic-therapy framing is now hard to avoid.
Top 20% journal 🔗 Metabolites Review 🗓️ Oct 27

🏥 Insurance denials for GLP-1 drugs vary sharply by payer type

  • A study tracking GLP-1 prescription denials across commercial, Medicare, and Medicaid coverage from 2018–2024 found that access remains strongly shaped by payer type and utilization management policies.
  • A companion analysis of Medicaid data found that as of late 2024, only 13 states covered GLP-1 drugs for obesity, and prescriptions were heavily concentrated in those states — reaching 16.2 per 1,000 Medicaid beneficiaries in covered states by Q4 2024.
💡 Where you live and who insures you still determines whether you can get these drugs.
🔗 Health affairs scholar Journal Article 🗓️ Oct 28

🍺 Semaglutide cut alcohol intake in rats — and eased withdrawal anxiety

  • In alcohol-preferring rats, semaglutide reduced voluntary alcohol consumption in a dose-dependent manner and produced anxiolytic effects during withdrawal in an open-field test.
  • The drug also reduced GABAergic signaling in a brain region linked to stress and emotional regulation. These are animal findings, and the jump to human alcohol use disorder treatment requires dedicated clinical trials — but the mechanistic signal is consistent with earlier work in this area.
💡 Animal data on semaglutide and alcohol are promising; human trial evidence is still needed.
🎖️ Top 10% journal 🔗 Neuropharmacology Journal Article 🗓️ Oct 27

🫀 GLP-1 drugs linked to lower cardiac death and stroke across 82,000-patient meta-analysis

  • A meta-analysis of 12 randomized controlled trials found GLP-1 drugs associated with lower rates of cardiac death, all-cause mortality, stroke, and revascularization compared to placebo or standard care.
  • The reductions in myocardial infarction and heart failure hospitalization did not reach statistical significance — so the cardiovascular benefit appears real but is not uniform across every cardiac endpoint.
💡 GLP-1 drugs cut cardiac death and stroke, but the heart failure benefit remains unconfirmed.
🔗 Monaldi Arch Chest Dis Journal Article 🗓️ Oct 28

Implications

The same week that retatrutide's provisional 28% weight-loss figure circulated widely, two separate analyses confirmed that access to existing GLP-1 drugs is still determined more by zip code and insurance type than by clinical need. The unresolved tension: if weight regain is near-universal after stopping, and coverage remains this fragmented, who actually benefits long-term?

Studies in this issue

Primary sources used for this newsletter.

  1. Glucagon-like-peptide-1 receptor agonists and their impact on major heart and blood vessel health outcomes
    key findingMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace2026-10-28PMID 42948977